Eli Lilly Stock Surges Over 5% Following FDA Approval of Weight-Loss Drug Foundayo

Original: Eli Lilly (LLY) stock soars after FDA approves Foundayo - can this weight-loss pill drive massive growth as investors bet big on obesity drug boom

The Economic Times•Apr 1, 20263 min

In a Nutshell

Eli Lilly's stock rose by over 5% after the U.S. Food and Drug Administration approved its oral weight-loss drug, Foundayo. This approval positions Eli Lilly strongly in the expanding obesity treatment market, with clinical trials showing significant weight loss among users.

Key Points

01Eli Lilly's stock increased by more than 5% after FDA approval of Foundayo.
02The drug, orforglipron, is expected to capture a significant market share in obesity treatment.
03Patients in trials lost an average of 12% to 15% of their body weight.
04Foundayo will be priced at $25 per month for insured patients and $149 for self-pay users.
05Analysts maintain a Buy rating for Eli Lilly, with a target price of $1,177.40.

In-Article Ad

Full Summary

Shares of Eli Lilly (LLY) surged over 5% on Wednesday following the U.S. Food and Drug Administration's approval of its new oral weight-loss drug, Foundayo (scientifically known as orforglipron). This marks Eli Lilly's second FDA-approved obesity therapy, enhancing its position in the rapidly growing obesity treatment market. Clinical trials indicated that adults taking the highest dose of Foundayo lost an average of 27 pounds, or 12.4% of their body weight. The drug is set to be available through the LillyDirect platform at $25 per month for commercially insured patients and $149 for self-pay users, with Medicare Part D patients able to access it for $50 per month starting July 2026. Analysts remain optimistic, maintaining a Buy rating with an average price target of $1,177.40. As the market anticipates the drug's impact on revenue growth, Eli Lilly's next earnings update is scheduled for April 30, 2026.

Key Figures

27 pounds

Average weight loss in clinical trials

$25

Monthly cost for commercially insured patients

$149

Monthly cost for self-pay users

12.4%

Percentage of body weight lost on average

In-Article Ad

Why It Matters

The approval of Foundayo could lead to increased accessibility of effective weight-loss treatment for patients, potentially influencing healthcare costs and insurance coverage.

Who is affected

Patients seeking weight-loss solutions and healthcare providers.

What to know

Patients should consult their healthcare providers about the availability and suitability of Foundayo for their weight-loss needs.

FAQ

In trials, patients lost about 12%–15% of their body weight on average.

It strengthens the company’s position in the growing obesity treatment market.

Read the original article →